Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Hepatitis C

  Free Subscription


Articles published in PLoS One

Retrieve available abstracts of 221 articles:
HTML format
Text format



Single Articles


    January 2018
  1. KONDILI LA, Gaeta GB, Ieluzzi D, Zignego AL, et al
    Correction: Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study.
    PLoS One. 2018;13:e0190803.
    PubMed     Text format     Abstract available


  2. CHARRE C, Cotte L, Kramer R, Miailhes P, et al
    Hepatitis C virus spread from HIV-positive to HIV-negative men who have sex with men.
    PLoS One. 2018;13:e0190340.
    PubMed     Text format     Abstract available


  3. CHEN SH, Lai HC, Chiang IP, Su WP, et al
    Changes in liver stiffness measurement using acoustic radiation force impulse elastography after antiviral therapy in patients with chronic hepatitis C.
    PLoS One. 2018;13:e0190455.
    PubMed     Text format     Abstract available


  4. BOLOTIN S, Feld JJ, Garber G, Wong WWL, et al
    Population-based estimate of hepatitis C virus prevalence in Ontario, Canada.
    PLoS One. 2018;13:e0191184.
    PubMed     Text format     Abstract available


  5. CHENG CH, Lin CC, Chen HL, Lin IT, et al
    Genotype distribution and treatment response among incarcerated drug-dependent patients with chronic hepatitis C infection.
    PLoS One. 2018;13:e0191799.
    PubMed     Text format     Abstract available


  6. DEL CAMPO JA, Garcia-Valdecasas M, Gil-Gomez A, Rojas A, et al
    Simvastatin and metformin inhibit cell growth in hepatitis C virus infected cells via mTOR increasing PTEN and autophagy.
    PLoS One. 2018;13:e0191805.
    PubMed     Text format     Abstract available


  7. NDJOYI-MBIGUINO A, Kombe Kombe AJ, Bivigou-Mboumba B, Zoa-Assoumou S, et al
    Low prevalence of HCV infection with predominance of genotype 4 among HIV patients living in Libreville, Gabon.
    PLoS One. 2018;13:e0190529.
    PubMed     Text format     Abstract available


  8. SAFREED-HARMON K, Hetherington KL, Aleman S, Alho H, et al
    Policy responses to hepatitis C in the Nordic countries: Gaps and discrepant reporting in the Hep-Nordic study.
    PLoS One. 2018;13:e0190146.
    PubMed     Text format     Abstract available


  9. ZAHR NM
    Peripheral TNFalpha elevations in abstinent alcoholics are associated with hepatitis C infection.
    PLoS One. 2018;13:e0191586.
    PubMed     Text format     Abstract available


  10. KELLY ML, Riordan SM, Bopage R, Lloyd AR, et al
    Capacity of non-invasive hepatic fibrosis algorithms to replace transient elastography to exclude cirrhosis in people with hepatitis C virus infection: A multi-centre observational study.
    PLoS One. 2018;13:e0192763.
    PubMed     Text format     Abstract available


  11. ANADOL E, Lust K, Boesecke C, Schwarze-Zander C, et al
    Exposure to previous cART is associated with significant liver fibrosis and cirrhosis in human immunodeficiency virus-infected patients.
    PLoS One. 2018;13:e0191118.
    PubMed     Text format     Abstract available


  12. RATTANAVIPAPONG W, Anothaisintawee T, Teerawattananon Y
    Revisiting policy on chronic HCV treatment under the Thai Universal Health Coverage: An economic evaluation and budget impact analysis.
    PLoS One. 2018;13:e0193112.
    PubMed     Text format     Abstract available


  13. TARAMASSO L, Di Biagio A, Bovis F, Nicolini LA, et al
    Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir +/- ribavirin in HIV/HCV co-infected patients.
    PLoS One. 2018;13:e0192627.
    PubMed     Text format     Abstract available


  14. CHENG PN, Chiu YC, Chiu HC, Chien SC, et al
    The characteristics of residents with unawareness of hepatitis C virus infection in community.
    PLoS One. 2018;13:e0193251.
    PubMed     Text format     Abstract available


  15. MAPOURE NY, Budzi MN, Eloumou SAFB, Malongue A, et al
    Neurological manifestations in chronic hepatitis C patients receiving care in a reference hospital in sub-Saharan Africa: A cross-sectional study.
    PLoS One. 2018;13:e0192406.
    PubMed     Text format     Abstract available


  16. MAUNOURY F, Clement A, Nwankwo C, Levy-Bachelot L, et al
    Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France.
    PLoS One. 2018;13:e0194329.
    PubMed     Text format     Abstract available


  17. DI POTO C, He S, Varghese RS, Zhao Y, et al
    Identification of race-associated metabolite biomarkers for hepatocellular carcinoma in patients with liver cirrhosis and hepatitis C virus infection.
    PLoS One. 2018;13:e0192748.
    PubMed     Text format     Abstract available


  18. MOTOYAMA H, Tamori A, Kubo S, Uchida-Kobayashi S, et al
    Stagnation of histopathological improvement is a predictor of hepatocellular carcinoma development after hepatitis C virus eradication.
    PLoS One. 2018;13:e0194163.
    PubMed     Text format     Abstract available


  19. ZEKRI AN, El-Sisi ER, Youssef ASE, Kamel MM, et al
    MicroRNA Signatures for circulating CD133-positive cells in hepatocellular carcinoma with HCV infection.
    PLoS One. 2018;13:e0193709.
    PubMed     Text format     Abstract available


  20. CARABALLO CORTES K, Rosinska M, Janiak M, Stepien M, et al
    Next-generation sequencing analysis of a cluster of hepatitis C virus infections in a haematology and oncology center.
    PLoS One. 2018;13:e0194816.
    PubMed     Text format     Abstract available


  21. NEMOZ B, Roger L, Leroy V, Poveda JD, et al
    Evaluation of the cobas(R) GT hepatitis C virus genotyping assay in G1-6 viruses including low viral loads and LiPA failures.
    PLoS One. 2018;13:e0194396.
    PubMed     Text format     Abstract available


  22. LI CW, Yang CJ, Sun HY, Tsai MS, et al
    Changing seroprevalence of hepatitis C virus infection among HIV-positive patients in Taiwan.
    PLoS One. 2018;13:e0194149.
    PubMed     Text format     Abstract available


  23. DES JARLAIS DC, Cooper HLF, Arasteh K, Feelemyer J, et al
    Potential geographic "hotspots" for drug-injection related transmission of HIV and HCV and for initiation into injecting drug use in New York City, 2011-2015, with implications for the current opioid epidemic in the US.
    PLoS One. 2018;13:e0194799.
    PubMed     Text format     Abstract available


  24. TI L, Socias ME, Wood E, Milloy MJ, et al
    The impact of methadone maintenance therapy on access to regular physician care regarding hepatitis C among people who inject drugs.
    PLoS One. 2018;13:e0194162.
    PubMed     Text format     Abstract available


  25. YAMAZAKI T, Joshita S, Umemura T, Usami Y, et al
    Changes in serum levels of autotaxin with direct-acting antiviral therapy in patients with chronic hepatitis C.
    PLoS One. 2018;13:e0195632.
    PubMed     Text format     Abstract available


  26. GOLIZEH M, Melendez-Pena CE, Ward BJ, Saeed S, et al
    Proteomic fingerprinting in HIV/HCV co-infection reveals serum biomarkers for the diagnosis of fibrosis staging.
    PLoS One. 2018;13:e0195148.
    PubMed     Text format     Abstract available


  27. FACENTE SN, Grebe E, Burk K, Morris MD, et al
    Estimated hepatitis C prevalence and key population sizes in San Francisco: A foundation for elimination.
    PLoS One. 2018;13:e0195575.
    PubMed     Text format     Abstract available


  28. LU Y, Jin X, Duan CA, Chang F, et al
    Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naive patients in China.
    PLoS One. 2018;13:e0195117.
    PubMed     Text format     Abstract available


  29. HAMADA K, Saitoh S, Nishino N, Fukushima D, et al
    Shear wave elastography predicts hepatocellular carcinoma risk in hepatitis C patients after sustained virological response.
    PLoS One. 2018;13:e0195173.
    PubMed     Text format     Abstract available


  30. MASHIBA T, Joko K, Kurosaki M, Ochi H, et al
    Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group.
    PLoS One. 2018;13:e0194704.
    PubMed     Text format     Abstract available


  31. FISHER KA, Cahill LM, Broyles S, Rorke M, et al
    Knowledge of hepatitis C status moderates the relationship between history of drug treatment and sterile syringe use.
    PLoS One. 2018;13:e0196157.
    PubMed     Text format     Abstract available


  32. WASITTHANKASEM R, Vichaiwattana P, Siripon N, Posuwan N, et al
    Liver disease burden and required treatment expenditures for hepatitis C virus (HCV) infection in Thailand: Implications for HCV elimination in the new therapeutic era, a population-based study.
    PLoS One. 2018;13:e0196301.
    PubMed     Text format     Abstract available


  33. OKUBO H, Ando H, Sorin Y, Nakadera E, et al
    Gadoxetic acid-enhanced magnetic resonance imaging to predict paritaprevir-induced hyperbilirubinemia during treatment of hepatitis C.
    PLoS One. 2018;13:e0196747.
    PubMed     Text format     Abstract available


  34. JIMENEZ-SOUSA MA, Gomez-Moreno AZ, Pineda-Tenor D, Medrano LM, et al
    The IL7RA rs6897932 polymorphism is associated with progression of liver fibrosis in patients with chronic hepatitis C: Repeated measurements design.
    PLoS One. 2018;13:e0197115.
    PubMed     Text format     Abstract available


  35. MAWATARI S, Oda K, Tabu K, Ijuin S, et al
    The co-existence of NS5A and NS5B resistance-associated substitutions is associated with virologic failure in Hepatitis C Virus genotype 1 patients treated with sofosbuvir and ledipasvir.
    PLoS One. 2018;13:e0198642.
    PubMed     Text format     Abstract available


  36. NAKANO T, Moriya K, Koike K, Horie T, et al
    Hepatitis C virus core protein triggers abnormal porphyrin metabolism in human hepatocellular carcinoma cells.
    PLoS One. 2018;13:e0198345.
    PubMed     Text format     Abstract available


  37. BLANCO RY, Loureiro CL, Villalba JA, Sulbaran YF, et al
    Decreasing prevalence of Hepatitis B and absence of Hepatitis C Virus infection in the Warao indigenous population of Venezuela.
    PLoS One. 2018;13:e0197662.
    PubMed     Text format     Abstract available


  38. GROTTENTHALER JM, Werner CR, Steurer M, Spengler U, et al
    Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation.
    PLoS One. 2018;13:e0197544.
    PubMed     Text format     Abstract available


  39. ZUCKERMAN A, Douglas A, Nwosu S, Choi L, et al
    Increasing success and evolving barriers in the hepatitis C cascade of care during the direct acting antiviral era.
    PLoS One. 2018;13:e0199174.
    PubMed     Text format     Abstract available


  40. HAINSWORTH SW, Dietze PM, Wilson DP, Sutton B, et al
    Hepatitis C virus notification rates in Australia are highest in socioeconomically disadvantaged areas.
    PLoS One. 2018;13:e0198336.
    PubMed     Text format     Abstract available


  41. YEN YH, Kuo FY, Kee KM, Chang KC, et al
    APRI and FIB-4 in the evaluation of liver fibrosis in chronic hepatitis C patients stratified by AST level.
    PLoS One. 2018;13:e0199760.
    PubMed     Text format     Abstract available


  42. YAYA I, Roux P, Marcellin F, Wittkop L, et al
    Evolution of patients' socio-behavioral characteristics in the context of DAA: Results from the French ANRS CO13 HEPAVIH cohort of HIV-HCV co-infected patients.
    PLoS One. 2018;13:e0199874.
    PubMed     Text format     Abstract available


  43. SCHAEFER B, Viveiros A, Al-Zoairy R, Blach S, et al
    Disease burden of hepatitis C in the Austrian state of Tyrol - Epidemiological data and model analysis to achieve elimination by 2030.
    PLoS One. 2018;13:e0200750.
    PubMed     Text format     Abstract available


  44. FACENTE SN, Grebe E, Burk K, Morris MD, et al
    Correction: Estimated hepatitis C prevalence and key population sizes in San Francisco: A foundation for elimination.
    PLoS One. 2018;13:e0200866.
    PubMed     Text format     Abstract available


  45. MIOTTO N, Mendes LC, Zanaga LP, Lazarini MSK, et al
    All-oral direct antiviral treatment for hepatitis C chronic infection in a real-life cohort: The role of cirrhosis and comorbidities in treatment response.
    PLoS One. 2018;13:e0199941.
    PubMed     Text format     Abstract available


  46. TIEU HV, Laeyendecker O, Nandi V, Rose R, et al
    Prevalence and mapping of hepatitis C infections among men who have sex with men in New York City.
    PLoS One. 2018;13:e0200269.
    PubMed     Text format     Abstract available


  47. SOOD A, Suryaprasad A, Trickey A, Kanchi S, et al
    The burden of hepatitis C virus infection in Punjab, India: A population-based serosurvey.
    PLoS One. 2018;13:e0200461.
    PubMed     Text format     Abstract available


  48. CUYPERS L, Perez AB, Chueca N, Aldamiz-Echevarria T, et al
    Relapse or reinfection after failing hepatitis C direct acting antiviral treatment: Unravelled by phylogenetic analysis.
    PLoS One. 2018;13:e0201268.
    PubMed     Text format     Abstract available


  49. MOTOYAMA H, Tamori A, Kubo S, Uchida-Kobayashi S, et al
    Correction: Stagnation of histopathological improvement is a predictor of hepatocellular carcinoma development after hepatitis C virus eradication.
    PLoS One. 2018;13:e0201423.
    PubMed     Text format     Abstract available


  50. EVON DM, Stewart PW, Amador J, Serper M, et al
    A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study.
    PLoS One. 2018;13:e0196908.
    PubMed     Text format     Abstract available


  51. NEESGAARD B, Ruhwald M, Krarup HB, Weis N, et al
    Determination of anti-HCV and quantification of HCV-RNA and IP-10 from dried blood spots sent by regular mail.
    PLoS One. 2018;13:e0201629.
    PubMed     Text format     Abstract available


  52. DEMSISS W, Seid A, Fiseha T
    Hepatitis B and C: Seroprevalence, knowledge, practice and associated factors among medicine and health science students in Northeast Ethiopia.
    PLoS One. 2018;13:e0196539.
    PubMed     Text format     Abstract available


  53. PARK H, Jeong D, Nguyen P, Henry L, et al
    Economic and clinical burden of viral hepatitis in California: A population-based study with longitudinal analysis.
    PLoS One. 2018;13:e0196452.
    PubMed     Text format     Abstract available


  54. GOUNTAS I, Sypsa V, Blach S, Razavi H, et al
    HCV elimination among people who inject drugs. Modelling pre- and post-WHO elimination era.
    PLoS One. 2018;13:e0202109.
    PubMed     Text format     Abstract available


  55. HSIEH YC, Jeng WJ, Huang CH, Teng W, et al
    Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis.
    PLoS One. 2018;13:e0202777.
    PubMed     Text format     Abstract available


  56. WASITTHANKASEM R, Vichaiwattana P, Siripon N, Posuwan N, et al
    Birth-cohort HCV screening target in Thailand to expand and optimize the national HCV screening for public health policy.
    PLoS One. 2018;13:e0202991.
    PubMed     Text format     Abstract available


  57. WHITMILL A, Kim S, Rojas V, Gulraiz F, et al
    Signature molecules expressed differentially in a liver disease stage-specific manner by HIV-1 and HCV co-infection.
    PLoS One. 2018;13:e0202524.
    PubMed     Text format     Abstract available


  58. SILVA CMD, Peder LD, Guelere AM, Horvath JD, et al
    Seroprevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) among human immunodeficiency virus (HIV)-infected patients in an HBV endemic area in Brazil.
    PLoS One. 2018;13:e0203272.
    PubMed     Text format     Abstract available


  59. VALENCIA LA ROSA J, Ryan P, Alvaro-Meca A, Troya J, et al
    HCV seroconversion in a cohort of people who use drugs followed in a mobile harm reduction unit in Madrid: Breaking barriers for HCV elimination.
    PLoS One. 2018;13:e0204795.
    PubMed     Text format     Abstract available


  60. UCHIDA Y, Naiki K, Kouyama JI, Sugawara K, et al
    Serum asunaprevir concentrations showing correlation with the extent of liver fibrosis as a factor inducing liver injuries in patients with genotype-1b hepatitis C virus receiving daclatasvir plus asunaprevir therapy.
    PLoS One. 2018;13:e0205600.
    PubMed     Text format     Abstract available


  61. JUANBELTZ R, Martinez-Baz I, San Miguel R, Goni-Esarte S, et al
    Impact of successful treatment with direct-acting antiviral agents on health-related quality of life in chronic hepatitis C patients.
    PLoS One. 2018;13:e0205277.
    PubMed     Text format     Abstract available


  62. SCHNELL G, Krishnan P, Tripathi R, Beyer J, et al
    Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvir.
    PLoS One. 2018;13:e0205186.
    PubMed     Text format     Abstract available


  63. FAHMY AM, Khabir M, Blanchet M, Labonte P, et al
    LC3B is not recruited along with the autophagy elongation complex (ATG5-12/16L1) at HCV replication site and is dispensable for viral replication.
    PLoS One. 2018;13:e0205189.
    PubMed     Text format     Abstract available


    January 2017
  64. ASSELAH T, Moreno C, Sarrazin C, Gschwantler M, et al
    Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naive Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response.
    PLoS One. 2017;12:e0168713.
    PubMed     Text format     Abstract available


  65. ZHU Z, Tran H, Mathahs MM, Moninger TO, et al
    HCV Induces Telomerase Reverse Transcriptase, Increases Its Catalytic Activity, and Promotes Caspase Degradation in Infected Human Hepatocytes.
    PLoS One. 2017;12:e0166853.
    PubMed     Text format     Abstract available


  66. WANG SC, Lai KR, Li CY, Chiang CS, et al
    The Paradoxical Effects of Different Hepatitis C Viral Loads on Host DNA Damage and Repair Abilities.
    PLoS One. 2017;12:e0164281.
    PubMed     Text format     Abstract available


  67. STAHMEYER JT, Rossol S, Liersch S, Guerra I, et al
    Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany.
    PLoS One. 2017;12:e0169401.
    PubMed     Text format     Abstract available


  68. PUGA MA, Bandeira LM, Pompilio MA, Croda J, et al
    Prevalence and Incidence of HCV Infection among Prisoners in Central Brazil.
    PLoS One. 2017;12:e0169195.
    PubMed     Text format     Abstract available


  69. KIM DY, Han KH, Jun B, Kim TH, et al
    Estimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea.
    PLoS One. 2017;12:e0167770.
    PubMed     Text format     Abstract available


  70. HU J, Gu X, Tao X, Qian Y, et al
    Prevalence and Trends of HIV, Syphilis, and HCV in Migrant and Resident Men Who Have Sex with Men in Shandong, China: Results from a Serial Cross-Sectional Study.
    PLoS One. 2017;12:e0170443.
    PubMed     Text format     Abstract available


  71. DEGRE D, Serste T, Lasser L, Delwaide J, et al
    Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium.
    PLoS One. 2017;12:e0170933.
    PubMed     Text format     Abstract available


  72. INOUE T, Hmwe SS, Shimada N, Kato K, et al
    Clinical Significance of Two Real-Time PCR Assays for Chronic Hepatitis C Patients Receiving Protease Inhibitor-Based Therapy.
    PLoS One. 2017;12:e0170667.
    PubMed     Text format     Abstract available


  73. ZHAI N, Li H, Song H, Yang Y, et al
    Hepatitis C Virus Induces MDSCs-Like Monocytes through TLR2/PI3K/AKT/STAT3 Signaling.
    PLoS One. 2017;12:e0170516.
    PubMed     Text format     Abstract available


  74. GAMBATO M, Caro-Perez N, Gonzalez P, Canete N, et al
    Correction: Neutrophil and Monocyte Function in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy with Regimens Containing Protease Inhibitors with and without Interferon.
    PLoS One. 2017;12:e0170913.
    PubMed     Text format     Abstract available


  75. TSUTSUMI T, Okushin K, Enooku K, Fujinaga H, et al
    Nonstructural 5A Protein of Hepatitis C Virus Interferes with Toll-Like Receptor Signaling and Suppresses the Interferon Response in Mouse Liver.
    PLoS One. 2017;12:e0170461.
    PubMed     Text format     Abstract available


  76. NIEN HC, Hsu SJ, Su TH, Yang PJ, et al
    High Serum Lipopolysaccharide-Binding Protein Level in Chronic Hepatitis C Viral Infection Is Reduced by Anti-Viral Treatments.
    PLoS One. 2017;12:e0170028.
    PubMed     Text format     Abstract available


  77. ZHANG C, Hua R, Cui Y, Wang S, et al
    Comprehensive mapping of antigen specific T cell responses in hepatitis C virus infected patients with or without spontaneous viral clearance.
    PLoS One. 2017;12:e0171217.
    PubMed     Text format     Abstract available


  78. WELSCH C, Efinger M, von Wagner M, Herrmann E, et al
    Ongoing liver inflammation in patients with chronic hepatitis C and sustained virological response.
    PLoS One. 2017;12:e0171755.
    PubMed     Text format     Abstract available


  79. RUIZ-EXTREMERA A, Pavon-Castillero EJ, Florido M, Munoz de Rueda P, et al
    Influence of HLA class I, HLA class II and KIRs on vertical transmission and chronicity of hepatitis C virus in children.
    PLoS One. 2017;12:e0172527.
    PubMed     Text format     Abstract available


  80. MIYAKI E, Hiraga N, Imamura M, Uchida T, et al
    Interferon alpha treatment stimulates interferon gamma expression in type I NKT cells and enhances their antiviral effect against hepatitis C virus.
    PLoS One. 2017;12:e0172412.
    PubMed     Text format     Abstract available


  81. KONDILI LA, Gaeta GB, Ieluzzi D, Zignego AL, et al
    Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study.
    PLoS One. 2017;12:e0172159.
    PubMed     Text format     Abstract available


  82. LIN SY, Lin CL, Ju SW, Wang IK, et al
    Increasing risk of cataract in HCV patients receiving anti-HCV therapy: A nationwide cohort study.
    PLoS One. 2017;12:e0173125.
    PubMed     Text format     Abstract available


  83. RALLON N, Garcia M, Garcia-Samaniego J, Rodriguez N, et al
    HCV coinfection contributes to HIV pathogenesis by increasing immune exhaustion in CD8 T-cells.
    PLoS One. 2017;12:e0173943.
    PubMed     Text format     Abstract available


  84. GUPTA N, Kabahizi J, Mukabatsinda C, Walker TD, et al
    "Waiting for DAAs": A retrospective chart review of patients with untreated hepatitis C in Rwanda.
    PLoS One. 2017;12:e0174148.
    PubMed     Text format     Abstract available


  85. GUINOISEAU T, Moreau A, Hohnadel G, Ngo-Giang-Huong N, et al
    Deep sequencing is an appropriate tool for the selection of unique Hepatitis C virus (HCV) variants after single genomic amplification.
    PLoS One. 2017;12:e0174852.
    PubMed     Text format     Abstract available


  86. KACZMAREK DJ, Kokordelis P, Kramer B, Glassner A, et al
    Alterations of the NK cell pool in HIV/HCV co-infection.
    PLoS One. 2017;12:e0174465.
    PubMed     Text format     Abstract available


  87. CHEN H, Chen L
    Estimating cost-effectiveness associated with all-oral regimen for chronic hepatitis C in China.
    PLoS One. 2017;12:e0175189.
    PubMed     Text format     Abstract available


  88. KOMOLMIT P, Charoensuk K, Thanapirom K, Suksawatamnuay S, et al
    Correction of vitamin D deficiency facilitated suppression of IP-10 and DPP IV levels in patients with chronic hepatitis C: A randomised double-blinded, placebo-control trial.
    PLoS One. 2017;12:e0174608.
    PubMed     Text format     Abstract available


  89. FERNANDEZ-CABALLERO JA, Alvarez M, Chueca N, Perez AB, et al
    The cobas(R) HCV GT is a new tool that accurately identifies Hepatitis C virus genotypes for clinical practice.
    PLoS One. 2017;12:e0175564.
    PubMed     Text format     Abstract available


  90. YANG CM, Yoon JC, Park JH, Lee JM, et al
    Hepatitis C virus impairs natural killer cell activity via viral serine protease NS3.
    PLoS One. 2017;12:e0175793.
    PubMed     Text format     Abstract available


  91. CHLIBEK R, Smetana J, Sosovickova R, Gal P, et al
    Prevalence of hepatitis C virus in adult population in the Czech Republic - time for birth cohort screening.
    PLoS One. 2017;12:e0175525.
    PubMed     Text format     Abstract available


  92. LE GUILLOU-GUILLEMETTE H, Pivert A, Bouthry E, Henquell C, et al
    Natural non-homologous recombination led to the emergence of a duplicated V3-NS5A region in HCV-1b strains associated with hepatocellular carcinoma.
    PLoS One. 2017;12:e0174651.
    PubMed     Text format     Abstract available


  93. CAPILENO YA, Van den Bergh R, Donchunk D, Hinderaker SG, et al
    Management of chronic Hepatitis C at a primary health clinic in the high-burden context of Karachi, Pakistan.
    PLoS One. 2017;12:e0175562.
    PubMed     Text format     Abstract available


  94. PENE V, Lemasson M, Harper F, Pierron G, et al
    Role of cleavage at the core-E1 junction of hepatitis C virus polyprotein in viral morphogenesis.
    PLoS One. 2017;12:e0175810.
    PubMed     Text format     Abstract available


  95. FRIAS M, Rivero-Juarez A, Tellez F, Perez-Perez M, et al
    Spontaneous clearance of chronic hepatitis C is rare in HIV-infected patients after effective use of combination antiretroviral therapy.
    PLoS One. 2017;12:e0177141.
    PubMed     Text format     Abstract available


  96. MOQUEET N, Kanagaratham C, Gill MJ, Hull M, et al
    A prognostic model for development of significant liver fibrosis in HIV-hepatitis C co-infection.
    PLoS One. 2017;12:e0176282.
    PubMed     Text format     Abstract available


  97. BIRGER RB, Le T, Kouyos RD, Grenfell BT, et al
    The impact of HCV therapy in a high HIV-HCV prevalence population: A modeling study on people who inject drugs in Ho Chi Minh City, Vietnam.
    PLoS One. 2017;12:e0177195.
    PubMed     Text format     Abstract available


  98. CHANG CC, Hsu HJ, Yen JH, Lo SY, et al
    A Sequence in the loop domain of hepatitis C virus E2 protein identified in silico as crucial for the selective binding to human CD81.
    PLoS One. 2017;12:e0177383.
    PubMed     Text format     Abstract available


  99. WASITTHANKASEM R, Vichaiwattana P, Siripon N, Posuwan N, et al
    Assessment of hepatitis C virus infection in two adjacent Thai provinces with drastically different seroprevalence.
    PLoS One. 2017;12:e0177022.
    PubMed     Text format     Abstract available


  100. D'ARMINIO MONFORTE A, Cozzi-Lepri A, Ceccherini-Silberstein F, De Luca A, et al
    Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort.
    PLoS One. 2017;12:e0177402.
    PubMed     Text format     Abstract available


  101. AGGARWAL R, Chen Q, Goel A, Seguy N, et al
    Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India.
    PLoS One. 2017;12:e0176503.
    PubMed     Text format     Abstract available


  102. CENTO V, Nguyen THT, Di Carlo D, Biliotti E, et al
    Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens.
    PLoS One. 2017;12:e0177352.
    PubMed     Text format     Abstract available


  103. ECKHARDT B, Winkelstein ER, Shu MA, Carden MR, et al
    Risk factors for hepatitis C seropositivity among young people who inject drugs in New York City: Implications for prevention.
    PLoS One. 2017;12:e0177341.
    PubMed     Text format     Abstract available


  104. HUNDIE GB, Raj VS, GebreMichael D, Pas SD, et al
    Genetic diversity of hepatitis C virus in Ethiopia.
    PLoS One. 2017;12:e0179064.
    PubMed     Text format     Abstract available


  105. NAIK AS, Owsianka A, Palmer BA, O'Halloran CJ, et al
    Reverse epitope mapping of the E2 glycoprotein in antibody associated hepatitis C virus.
    PLoS One. 2017;12:e0175349.
    PubMed     Text format     Abstract available


  106. EL HADAD S, Al-Hamdan H, Linjawi S
    Partial sequencing analysis of the NS5B region confirmed the predominance of hepatitis C virus genotype 1 infection in Jeddah, Saudi Arabia.
    PLoS One. 2017;12:e0178225.
    PubMed     Text format     Abstract available


  107. ALVARO-MECA A, Berenguer J, Diaz A, Micheloud D, et al
    Stroke in HIV-infected individuals with and without HCV coinfection in Spain in the combination antiretroviral therapy era.
    PLoS One. 2017;12:e0179493.
    PubMed     Text format     Abstract available


  108. CHU PS, Nakamoto N, Taniki N, Ojiro K, et al
    On-treatment decrease of NKG2D correlates to early emergence of clinically evident hepatocellular carcinoma after interferon-free therapy for chronic hepatitis C.
    PLoS One. 2017;12:e0179096.
    PubMed     Text format     Abstract available


  109. LEE JW, Kim W, Kwon EK, Kim Y, et al
    Immunological dynamics associated with rapid virological response during the early phase of type I interferon therapy in patients with chronic hepatitis C.
    PLoS One. 2017;12:e0179094.
    PubMed     Text format     Abstract available


  110. CAPILENO YA, Van den Bergh R, Donchuk D, Hinderaker SG, et al
    Correction: Management of chronic Hepatitis C at a primary health clinic in the high-burden context of Karachi, Pakistan.
    PLoS One. 2017;12:e0180286.
    PubMed     Text format     Abstract available


  111. MASCIA C, Vita S, Zuccala P, Marocco R, et al
    Changes in inflammatory biomarkers in HCV-infected patients undergoing direct acting antiviral-containing regimens with or without interferon.
    PLoS One. 2017;12:e0179400.
    PubMed     Text format     Abstract available


  112. ELSHERIF O, Bannan C, Keating S, McKiernan S, et al
    Outcomes from a large 10 year hepatitis C treatment programme in people who inject drugs: No effect of recent or former injecting drug use on treatment adherence or therapeutic response.
    PLoS One. 2017;12:e0178398.
    PubMed     Text format     Abstract available


  113. LIN HC, Xirasagar S, Lee HC, Huang CC, et al
    Association of Alzhemier's disease with hepatitis C among patients with bipolar disorder.
    PLoS One. 2017;12:e0179312.
    PubMed     Text format     Abstract available


  114. ISHIZAKI A, Tran VT, Nguyen CH, Tanimoto T, et al
    Discrepancies in prevalence trends for HIV, hepatitis B virus, and hepatitis C virus in Haiphong, Vietnam from 2007 to 2012.
    PLoS One. 2017;12:e0179616.
    PubMed     Text format     Abstract available


  115. BELAUNZARAN-ZAMUDIO PF, Mosqueda-Gomez JL, Macias-Hernandez A, Sierra-Madero JG, et al
    Risk factors for prevalent hepatitis C virus-infection among inmates in a state prison system in Mexico.
    PLoS One. 2017;12:e0179931.
    PubMed     Text format     Abstract available


  116. SHIU TY, Huang SM, Shih YL, Chu HC, et al
    Correction: Hepatitis C Virus Core Protein Down-Regulates p21Waf1/Cip1 and Inhibits Curcumin-Induced Apoptosis through MicroRNA-345 Targeting in Human Hepatoma Cells.
    PLoS One. 2017;12:e0181299.
    PubMed     Text format     Abstract available


  117. SNOW KJ, Richards AH, Kinner SA
    Use of multiple data sources to estimate hepatitis C seroprevalence among prisoners: A retrospective cohort study.
    PLoS One. 2017;12:e0180646.
    PubMed     Text format     Abstract available


  118. LEVENTER-ROBERTS M, Hammerman A, Brufman I, Hoshen M, et al
    Effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir for hepatitis C virus in clinical practice: A population-based observational study.
    PLoS One. 2017;12:e0176858.
    PubMed     Text format     Abstract available


  119. LOPEZ-RODRIGUEZ R, Hernandez-Bartolome A, Borque MJ, Rodriguez-Munoz Y, et al
    Interferon-related genetic markers of necroinflammatory activity in chronic hepatitis C.
    PLoS One. 2017;12:e0180927.
    PubMed     Text format     Abstract available


  120. DALGARD O, Weiland O, Noraberg G, Karlsen L, et al
    Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study.
    PLoS One. 2017;12:e0179764.
    PubMed     Text format     Abstract available


  121. ANDRE-GARNIER E, Besse B, Rodallec A, Ribeyrol O, et al
    An NS5A single optimized method to determine genotype, subtype and resistance profiles of Hepatitis C strains.
    PLoS One. 2017;12:e0179562.
    PubMed     Text format     Abstract available


  122. NEUKAM K, Martinez AP, Culasso ACA, Ridruejo E, et al
    NS3 genomic sequencing and phylogenetic analysis as alternative to a commercially available assay to reliably determine hepatitis C virus subtypes 1a and 1b.
    PLoS One. 2017;12:e0182193.
    PubMed     Text format     Abstract available


  123. RUSSELLI G, Pizzillo P, Iannolo G, Barbera F, et al
    HCV replication in gastrointestinal mucosa: Potential extra-hepatic viral reservoir and possible role in HCV infection recurrence after liver transplantation.
    PLoS One. 2017;12:e0181683.
    PubMed     Text format     Abstract available


  124. SABET S, George MA, El-Shorbagy HM, Bassiony H, et al
    Gelatin nanoparticles enhance delivery of hepatitis C virus recombinant NS2 gene.
    PLoS One. 2017;12:e0181723.
    PubMed     Text format     Abstract available


  125. MERDAN M, Bekiryazici Z, Kesemen T, Khaniyev T, et al
    Deterministic stability and random behavior of a Hepatitis C model.
    PLoS One. 2017;12:e0181571.
    PubMed     Text format     Abstract available


  126. STELZL E, Haas B, Bauer B, Zhang S, et al
    First identification of a recombinant form of hepatitis C virus in Austrian patients by full-genome next generation sequencing.
    PLoS One. 2017;12:e0181273.
    PubMed     Text format     Abstract available


  127. TAN WG, Zubkova I, Kachko A, Wells F, et al
    Qualitative differences in cellular immunogenicity elicited by hepatitis C virus T-Cell vaccines employing prime-boost regimens.
    PLoS One. 2017;12:e0181578.
    PubMed     Text format     Abstract available


  128. HUGHES MG JR, Tucker WW, Reddy S, Brier ME, et al
    Rate of hepatitis C viral clearance by human livers in human patients: Liver transplantation modeling primary infection and implications for studying entry inhibition.
    PLoS One. 2017;12:e0180719.
    PubMed     Text format     Abstract available


  129. SAGNELLI C, Uberti-Foppa C, Hasson H, Bellini G, et al
    Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV/HCV coinfected patients.
    PLoS One. 2017;12:e0181890.
    PubMed     Text format     Abstract available


  130. NAGAOKI Y, Imamura M, Aikata H, Daijo K, et al
    The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy.
    PLoS One. 2017;12:e0182710.
    PubMed     Text format     Abstract available


  131. HUANG CM, Chang KC, Hung CH, Chiu KW, et al
    Impact of PNPLA3 and IFNL3 polymorphisms on hepatic steatosis in Asian patients with chronic hepatitis C.
    PLoS One. 2017;12:e0182204.
    PubMed     Text format     Abstract available


  132. DE WEGGHELEIRE A, An S, De Baetselier I, Soeung P, et al
    A cross-sectional study of hepatitis C among people living with HIV in Cambodia: Prevalence, risk factors, and potential for targeted screening.
    PLoS One. 2017;12:e0183530.
    PubMed     Text format     Abstract available


  133. BUTT ZA, Shrestha N, Wong S, Kuo M, et al
    A syndemic approach to assess the effect of substance use and social disparities on the evolution of HIV/HCV infections in British Columbia.
    PLoS One. 2017;12:e0183609.
    PubMed     Text format     Abstract available


  134. COUTO I, Victoria M, Veloso VG, Rodrigues L, et al
    Prevalence and predictors for compensated Advanced Chronic Liver Disease (c-ACLD) in patients with chronic Hepatitis Delta Virus (HDV) infection.
    PLoS One. 2017;12:e0174453.
    PubMed     Text format     Abstract available


  135. CARRIERI MP, Marcellin F, Fressard L, Preau M, et al
    Suicide risk in a representative sample of people receiving HIV care: Time to target most-at-risk populations (ANRS VESPA2 French national survey).
    PLoS One. 2017;12:e0171645.
    PubMed     Text format     Abstract available


  136. MANICKAM C, Wachtman L, Martinot AJ, Giavedoni LD, et al
    Metabolic Dysregulation in Hepacivirus Infection of Common Marmosets (Callithrix jacchus).
    PLoS One. 2017;12:e0170240.
    PubMed     Text format     Abstract available


  137. SHIER MK, Iles JC, El-Wetidy MS, Ali HH, et al
    Molecular characterization and epidemic history of hepatitis C virus using core sequences of isolates from Central Province, Saudi Arabia.
    PLoS One. 2017;12:e0184163.
    PubMed     Text format     Abstract available


  138. HERMETET C, Dubois F, Gaudy-Graffin C, Bacq Y, et al
    Continuum of hepatitis C care in France: A 20-year cohort study.
    PLoS One. 2017;12:e0183232.
    PubMed     Text format     Abstract available


  139. KJAERGAARD M, Thiele M, Jansen C, Staehr Madsen B, et al
    High risk of misinterpreting liver and spleen stiffness using 2D shear-wave and transient elastography after a moderate or high calorie meal.
    PLoS One. 2017;12:e0173992.
    PubMed     Text format     Abstract available


  140. ZHENG Z, Sze CW, Keng CT, Al-Haddawi M, et al
    Hepatitis C virus mediated chronic inflammation and tumorigenesis in the humanised immune system and liver mouse model.
    PLoS One. 2017;12:e0184127.
    PubMed     Text format     Abstract available


  141. GOMEZ-MORENO AZ, Pineda-Tenor D, Jimenez-Sousa MA, Sanchez-Ruano JJ, et al
    Liver stiffness measurement predicts liver-related events in patients with chronic hepatitis C: A retrospective study.
    PLoS One. 2017;12:e0184404.
    PubMed     Text format     Abstract available


  142. VUTIEN P, Jin M, Le MH, Nguyen P, et al
    Regional differences in treatment rates for patients with chronic hepatitis C infection: Systematic review and meta-analysis.
    PLoS One. 2017;12:e0183851.
    PubMed     Text format     Abstract available


  143. CHI X, Zhao X, Wang W, Niu Y, et al
    Fusion expression of Occludin extracellular loops and an alpha-helical bundle: A new research model for tight junction.
    PLoS One. 2017;12:e0175516.
    PubMed     Text format     Abstract available


  144. CHEN HC, Chung CH, Wang CH, Lin JC, et al
    Increased risk of sudden sensorineural hearing loss in patients with hepatitis virus infection.
    PLoS One. 2017;12:e0175266.
    PubMed     Text format     Abstract available


  145. KEATING SM, Dodge JL, Norris PJ, Heitman J, et al
    The effect of HIV infection and HCV viremia on inflammatory mediators and hepatic injury-The Women's Interagency HIV Study.
    PLoS One. 2017;12:e0181004.
    PubMed     Text format     Abstract available


  146. NAKAMURA M, Kanda T, Jiang X, Haga Y, et al
    Serum microRNA-122 and Wisteria floribunda agglutinin-positive Mac-2 binding protein are useful tools for liquid biopsy of the patients with hepatitis B virus and advanced liver fibrosis.
    PLoS One. 2017;12:e0177302.
    PubMed     Text format     Abstract available


  147. TUDESQ JJ, Dunyach-Remy C, Combescure C, Doncesco R, et al
    Microbial translocation is correlated with HIV evolution in HIV-HCV co-infected patients.
    PLoS One. 2017;12:e0183372.
    PubMed     Text format     Abstract available


  148. ROSINSKA M, Parda N, Kolakowska A, Godzik P, et al
    Factors associated with hepatitis C prevalence differ by the stage of liver fibrosis: A cross-sectional study in the general population in Poland, 2012-2016.
    PLoS One. 2017;12:e0185055.
    PubMed     Text format     Abstract available


  149. CHIU NC, Su CW, Liu CA, Huang YH, et al
    Interval to vascularization development in cirrhotic precursor nodules in patients with hepatitis B and C virus co-infections.
    PLoS One. 2017;12:e0178841.
    PubMed     Text format     Abstract available


  150. UITTE DE WILLIGE S, Keane FM, Bowen DG, Malfliet JJMC, et al
    Circulating fibroblast activation protein activity and antigen levels correlate strongly when measured in liver disease and coronary heart disease.
    PLoS One. 2017;12:e0178987.
    PubMed     Text format     Abstract available


  151. NAGATY A, Abd El-Wahab EW
    Real-life results of sofosbuvir based therapy in chronic hepatitis C -naive and -experienced patients in Egypt.
    PLoS One. 2017;12:e0184654.
    PubMed     Text format     Abstract available


  152. KIM YA, Trinh S, Thura S, Kyi KP, et al
    Physician perspectives on the management of viral hepatitis and hepatocellular carcinoma in Myanmar.
    PLoS One. 2017;12:e0181603.
    PubMed     Text format     Abstract available


  153. BIADGO B, Shiferaw E, Woldu B, Alene KA, et al
    Transfusion-transmissible viral infections among blood donors at the North Gondar district blood bank, northwest Ethiopia: A three year retrospective study.
    PLoS One. 2017;12:e0180416.
    PubMed     Text format     Abstract available


  154. PARASCHIV S, Banica L, Nicolae I, Niculescu I, et al
    Epidemic dispersion of HIV and HCV in a population of co-infected Romanian injecting drug users.
    PLoS One. 2017;12:e0185866.
    PubMed     Text format     Abstract available


  155. GOUVEIA LR, Santos JC, Silva RD, Batista AD, et al
    Diagnosis of coinfection by schistosomiasis and viral hepatitis B or C using 1H NMR-based metabonomics.
    PLoS One. 2017;12:e0182196.
    PubMed     Text format     Abstract available


  156. UEMURA H, Tsukada K, Mizushima D, Aoki T, et al
    Interferon-free therapy with direct acting antivirals for HCV/HIV-1 co-infected Japanese patients with inherited bleeding disorders.
    PLoS One. 2017;12:e0186255.
    PubMed     Text format     Abstract available


  157. BURCHILL MA, Roby JA, Crochet N, Wind-Rotolo M, et al
    Rapid reversal of innate immune dysregulation in blood of patients and livers of humanized mice with HCV following DAA therapy.
    PLoS One. 2017;12:e0186213.
    PubMed     Text format     Abstract available


  158. RIOUALEN C, Da Costa Q, Chetrit B, Charafe-Jauffret E, et al
    HTS-Net: An integrated regulome-interactome approach for establishing network regulation models in high-throughput screenings.
    PLoS One. 2017;12:e0185400.
    PubMed     Text format     Abstract available


  159. DUFFY D, Mottez E, Ainsworth S, Buivan TP, et al
    An in vitro diagnostic certified point of care single nucleotide test for IL28B polymorphisms.
    PLoS One. 2017;12:e0183084.
    PubMed     Text format     Abstract available


  160. CHEN YI MEI SLG, Thompson AJ, Christensen B, Cunningham G, et al
    Sustained virological response halts fibrosis progression: A long-term follow-up study of people with chronic hepatitis C infection.
    PLoS One. 2017;12:e0185609.
    PubMed     Text format     Abstract available


  161. DULTZ G, Graubard BI, Martin P, Welker MW, et al
    Liver transplantation for chronic hepatitis C virus infection in the United States 2002-2014: An analysis of the UNOS/OPTN registry.
    PLoS One. 2017;12:e0186898.
    PubMed     Text format     Abstract available


  162. HARFOUCHE M, Chemaitelly H, Kouyoumjian SP, Mahmud S, et al
    Hepatitis C virus viremic rate in the Middle East and North Africa: Systematic synthesis, meta-analyses, and meta-regressions.
    PLoS One. 2017;12:e0187177.
    PubMed     Text format     Abstract available


  163. ROZERA G, Fabbri G, Lorenzini P, Mastrorosa I, et al
    Peripheral blood HIV-1 DNA dynamics in antiretroviral-treated HIV/HCV co-infected patients receiving directly-acting antivirals.
    PLoS One. 2017;12:e0187095.
    PubMed     Text format     Abstract available


  164. MAROT A, Henrion J, Knebel JF, Moreno C, et al
    Alcoholic liver disease confers a worse prognosis than HCV infection and non-alcoholic fatty liver disease among patients with cirrhosis: An observational study.
    PLoS One. 2017;12:e0186715.
    PubMed     Text format     Abstract available


  165. KONDILI LA, Gaeta GB, Brunetto MR, Di Leo A, et al
    Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network.
    PLoS One. 2017;12:e0185728.
    PubMed     Text format     Abstract available


  166. LOGGI E, Galli S, Vitale G, Di Donato R, et al
    Monitoring the treatment of hepatitis C with directly acting antivirals by serological and molecular methods.
    PLoS One. 2017;12:e0187755.
    PubMed     Text format     Abstract available


  167. KONERMAN MA, Lu D, Zhang Y, Thomson M, et al
    Assessing risk of fibrosis progression and liver-related clinical outcomes among patients with both early stage and advanced chronic hepatitis C.
    PLoS One. 2017;12:e0187344.
    PubMed     Text format     Abstract available


  168. SHIMIZU JF, Pereira CM, Bittar C, Batista MN, et al
    Multiple effects of toxins isolated from Crotalus durissus terrificus on the hepatitis C virus life cycle.
    PLoS One. 2017;12:e0187857.
    PubMed     Text format     Abstract available


  169. STROFFOLINI T, Sagnelli E, Andriulli A, Colloredo G, et al
    Sex difference in the interaction of alcohol intake, hepatitis B virus, and hepatitis C virus on the risk of cirrhosis.
    PLoS One. 2017;12:e0185710.
    PubMed     Text format     Abstract available


  170. GARRIGA C, Manzanares-Laya S, Garcia de Olalla P, Gorrindo P, et al
    Evolution of acute hepatitis C virus infection in a large European city: Trends and new patterns.
    PLoS One. 2017;12:e0187893.
    PubMed     Text format     Abstract available


  171. CARLUCCI JG, Farooq SA, Sizemore L, Rickles M, et al
    Low hepatitis C antibody screening rates among an insured population of Tennessean Baby Boomers.
    PLoS One. 2017;12:e0188624.
    PubMed     Text format     Abstract available


  172. BRAGA ACS, Carneiro BM, Batista MN, Akinaga MM, et al
    Heat shock proteins HSPB8 and DNAJC5B have HCV antiviral activity.
    PLoS One. 2017;12:e0188467.
    PubMed     Text format     Abstract available


  173. CANINI L, Imamura M, Kawakami Y, Uprichard SL, et al
    HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients.
    PLoS One. 2017;12:e0187409.
    PubMed     Text format     Abstract available


  174. COMSTOCK E, Kim CW, Murphy A, Emmanuel B, et al
    Transcriptional profiling of PBMCs unravels B cell mediated immunopathogenic imprints of HCV vasculitis.
    PLoS One. 2017;12:e0188314.
    PubMed     Text format     Abstract available


  175. LU G, Huang J, Yang Q, Xu H, et al
    Identification and genetic characterization of hepacivirus and pegivirus in commercial equine serum products in China.
    PLoS One. 2017;12:e0189208.
    PubMed     Text format     Abstract available


  176. SMITH JW, Kroker-Lobos MF, Lazo M, Rivera-Andrade A, et al
    Aflatoxin and viral hepatitis exposures in Guatemala: Molecular biomarkers reveal a unique profile of risk factors in a region of high liver cancer incidence.
    PLoS One. 2017;12:e0189255.
    PubMed     Text format     Abstract available


    January 2016
  177. POOVORAWAN K, Pan-Ngum W, White LJ, Soonthornworasiri N, et al
    Estimating the Impact of Expanding Treatment Coverage and Allocation Strategies for Chronic Hepatitis C in a Direct Antiviral Agent Era.
    PLoS One. 2016;11:e0163095.
    PubMed     Text format     Abstract available


  178. SAMIMI-RAD K, Rahimnia R, Sadeghi M, Malekpour SA, et al
    Epidemic History of Hepatitis C Virus among Patients with Inherited Bleeding Disorders in Iran.
    PLoS One. 2016;11:e0162492.
    PubMed     Text format     Abstract available


  179. WAN Z, Chen Q, Chen X, Duo L, et al
    HCV Diversity among Chinese and Burmese IDUs in Dehong, Yunnan, China.
    PLoS One. 2016;11:e0163062.
    PubMed     Text format     Abstract available


  180. JIMENEZ-SOUSA MA, Gutierrez-Rivas M, Alvaro-Meca A, Garcia-Alvarez M, et al
    NS3 Resistance-Associated Variants (RAVs) in Patients Infected with HCV Genotype 1a in Spain.
    PLoS One. 2016;11:e0163197.
    PubMed     Text format     Abstract available


  181. IDE T, Eguchi Y, Harada M, Ishii K, et al
    Evaluation of Resistance-Associated Substitutions in NS5A Using Direct Sequence and Cycleave Method and Treatment Outcome with Daclatasvir and Asunaprevir for Chronic Hepatitis C Genotype 1.
    PLoS One. 2016;11:e0163884.
    PubMed     Text format     Abstract available


  182. HASHIMOTO S, Yatsuhashi H, Abiru S, Yamasaki K, et al
    Rapid Increase in Serum Low-Density Lipoprotein Cholesterol Concentration during Hepatitis C Interferon-Free Treatment.
    PLoS One. 2016;11:e0163644.
    PubMed     Text format     Abstract available


  183. NGUYEN LT, Gray E, O'Leary A, Carr M, et al
    The Role of Hepatitis C Virus Core Antigen Testing in the Era of Direct Acting Antiviral Therapies: What We Can Learn from the Protease Inhibitors.
    PLoS One. 2016;11:e0163900.
    PubMed     Text format     Abstract available


  184. VAN SANTEN DK, de Vos AS, Matser A, Willemse SB, et al
    Cost-Effectiveness of Hepatitis C Treatment for People Who Inject Drugs and the Impact of the Type of Epidemic; Extrapolating from Amsterdam, the Netherlands.
    PLoS One. 2016;11:e0163488.
    PubMed     Text format     Abstract available


  185. MATSUNAMI K, Nishida N, Kaneko N, Ikeo K, et al
    Genome-Wide Association Study Identifies ZNF354C Variants Associated with Depression from Interferon-Based Therapy for Chronic Hepatitis C.
    PLoS One. 2016;11:e0164418.
    PubMed     Text format     Abstract available


  186. COLLI A, Fraquelli M, Prati D, Riva A, et al
    Deciding on Interferon-Free Treatment for Chronic Hepatitis C: Updating Liver Stiffness Cut-Off Values to Maximize Benefit.
    PLoS One. 2016;11:e0164452.
    PubMed     Text format     Abstract available


  187. GHORI NU, Shafique A, Hayat MQ, Anjum S, et al
    The Phylogeographic and Spatiotemporal Spread of HCV in Pakistani Population.
    PLoS One. 2016;11:e0164265.
    PubMed     Text format     Abstract available


  188. WHITE DA, Anderson ES, Pfeil SK, Deering LJ, et al
    Hepatitis C Virus Screening and Emergency Department Length of Stay.
    PLoS One. 2016;11:e0164831.
    PubMed     Text format     Abstract available


  189. DE AVILA AI, Gallego I, Soria ME, Gregori J, et al
    Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir.
    PLoS One. 2016;11:e0164691.
    PubMed     Text format     Abstract available


  190. ALRIC L, Besson C, Lapidus N, Jeannel J, et al
    Antiviral Treatment of HCV-Infected Patients with B-Cell Non-Hodgkin Lymphoma: ANRS HC-13 Lympho-C Study.
    PLoS One. 2016;11:e0162965.
    PubMed     Text format     Abstract available


  191. FLISIAK R, Shiffman M, Arenas J, Cheinquer H, et al
    A Randomized Study of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a in Combination with Ribavirin and Telaprevir in Patients with Genotype-1 Chronic Hepatitis C.
    PLoS One. 2016;11:e0164563.
    PubMed     Text format     Abstract available


  192. DAVITKOV P, Chandar AK, Hirsch A, Compan A, et al
    Treatment Selection Choices Should Not Be Based on Benefits or Costs Alone: A Head-to-Head Randomized Controlled Trial of Antiviral Drugs for Hepatitis C.
    PLoS One. 2016;11:e0163945.
    PubMed     Text format     Abstract available


  193. CHOI YH, Jin N, Kelly F, Sakthivel SK, et al
    Elevation of Alanine Aminotransferase Activity Occurs after Activation of the Cell-Death Signaling Initiated by Pattern-Recognition Receptors but before Activation of Cytolytic Effectors in NK or CD8+ T Cells in the Liver During Acute HCV Infection.
    PLoS One. 2016;11:e0165533.
    PubMed     Text format     Abstract available


  194. SIRAVENHA LG, Siravenha LQ, Madeira LD, Oliveira-Filho AB, et al
    Detection of HCV Persistent Infections in the Dental Pulp: A Novel Approach for the Detection of Past and Ancient Infections.
    PLoS One. 2016;11:e0165272.
    PubMed     Text format     Abstract available


  195. ITAKURA J, Kurosaki M, Hasebe C, Osaki Y, et al
    Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment Failure.
    PLoS One. 2016;11:e0165339.
    PubMed     Text format     Abstract available


  196. MERAT SJ, Molenkamp R, Wagner K, Koekkoek SM, et al
    Hepatitis C virus Broadly Neutralizing Monoclonal Antibodies Isolated 25 Years after Spontaneous Clearance.
    PLoS One. 2016;11:e0165047.
    PubMed     Text format     Abstract available


  197. ZHANG Y, Cao Y, Zhang R, Zhang X, et al
    Pre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b Patients.
    PLoS One. 2016;11:e0165658.
    PubMed     Text format     Abstract available


  198. LOFTFIELD E, O'Brien TR, Pfeiffer RM, Howell CD, et al
    Vitamin D Status and Virologic Response to HCV Therapy in the HALT-C and VIRAHEP-C Trials.
    PLoS One. 2016;11:e0166036.
    PubMed     Text format     Abstract available


  199. SU FH, Wu CS, Sung FC, Chang SN, et al
    Correction: Chronic Hepatitis C Virus Infection Is Associated with the Development of Rheumatoid Arthritis: A Nationwide Population-Based Study in Taiwan.
    PLoS One. 2016;11:e0166508.
    PubMed     Text format     Abstract available


  200. MIDGARD H, Bramness JG, Skurtveit S, Haukeland JW, et al
    Hepatitis C Treatment Uptake among Patients Who Have Received Opioid Substitution Treatment: A Population-Based Study.
    PLoS One. 2016;11:e0166451.
    PubMed     Text format     Abstract available


  201. PALMER BA, Fanning LJ
    Synonymous Co-Variation across the E1/E2 Gene Junction of Hepatitis C Virus Defines Virion Fitness.
    PLoS One. 2016;11:e0167089.
    PubMed     Text format     Abstract available


  202. LEE KY, Chen YH, Hsu SC, Yu MJ, et al
    Phosphorylation of Serine 235 of the Hepatitis C Virus Non-Structural Protein NS5A by Multiple Kinases.
    PLoS One. 2016;11:e0166763.
    PubMed     Text format     Abstract available


  203. AIKEN T, Garber A, Thomas D, Hamon N, et al
    Donor IFNL4 Genotype Is Associated with Early Post-Transplant Fibrosis in Recipients with Hepatitis C.
    PLoS One. 2016;11:e0166998.
    PubMed     Text format     Abstract available


  204. CHANG ML, Kuo CJ, Huang HC, Chu YY, et al
    Association between Leptin and Complement in Hepatitis C Patients with Viral Clearance: Homeostasis of Metabolism and Immunity.
    PLoS One. 2016;11:e0166712.
    PubMed     Text format     Abstract available


  205. GAMBATO M, Caro-Perez N, Gonzalez P, Canete N, et al
    Neutrophil and Monocyte Function in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy with Regimens Containing Protease Inhibitors with and without Interferon.
    PLoS One. 2016;11:e0166631.
    PubMed     Text format     Abstract available


  206. HAMAD HA, Thurston J, Teague T, Ackad E, et al
    The NS4A Cofactor Dependent Enhancement of HCV NS3 Protease Activity Correlates with a 4D Geometrical Measure of the Catalytic Triad Region.
    PLoS One. 2016;11:e0168002.
    PubMed     Text format     Abstract available


  207. PUIGVEHI M, Hernandez J, Broquetas T, Coll S, et al
    Diagnostic Accuracy of the Enhanced Liver Fibrosis (ELF(R)) Score Using HCV-Infected Serum Samples Cryopreserved for up to 25 Years.
    PLoS One. 2016;11:e0164883.
    PubMed     Text format     Abstract available


  208. NUNEZ-TORRES R, Macias J, Mancebo M, Frias M, et al
    The PNPLA3 Genetic Variant rs738409 Influences the Progression to Cirrhosis in HIV/Hepatitis C Virus Coinfected Patients.
    PLoS One. 2016;11:e0168265.
    PubMed     Text format     Abstract available


  209. SARRAZIN C, Manns M, Calleja JL, Garcia-Samaniego J, et al
    HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment.
    PLoS One. 2016;11:e0168544.
    PubMed     Text format     Abstract available


  210. EL-GHITANY EM, Farghaly AG, Farag S, Abd El-Wahab EW, et al
    Validation of EGCRISC for Chronic Hepatitis C Infection Screening and Risk Assessment in the Egyptian Population.
    PLoS One. 2016;11:e0168649.
    PubMed     Text format     Abstract available


  211. VILLANI R, Facciorusso A, Bellanti F, Tamborra R, et al
    DAAs Rapidly Reduce Inflammation but Increase Serum VEGF Level: A Rationale for Tumor Risk during Anti-HCV Treatment.
    PLoS One. 2016;11:e0167934.
    PubMed     Text format     Abstract available


  212. YASUI Y, Abe T, Kurosaki M, Higuchi M, et al
    Elastin Fiber Accumulation in Liver Correlates with the Development of Hepatocellular Carcinoma.
    PLoS One. 2016;11:e0154558.
    PubMed     Text format     Abstract available


  213. BOCHAROV G, Meyerhans A, Bessonov N, Trofimchuk S, et al
    Spatiotemporal Dynamics of Virus Infection Spreading in Tissues.
    PLoS One. 2016;11:e0168576.
    PubMed     Text format     Abstract available


  214. DE MIGUEL-DIEZ J, Lopez-de-Andres A, Jimenez-Garcia R, Puente-Maestu L, et al
    Trends in Epidemiology of COPD in HIV-Infected Patients in Spain (1997-2012).
    PLoS One. 2016;11:e0166421.
    PubMed     Text format     Abstract available


  215. NJOKU OS, Manak MM, O'Connell RJ, Shutt AL, et al
    An Evaluation of Selected Populations for HIV-1 Vaccine Cohort Development in Nigeria.
    PLoS One. 2016;11:e0166711.
    PubMed     Text format     Abstract available


  216. LIMA K, de Souza Leal E, Cavalcanti AM, Salustiano DM, et al
    Epidemiological, Clinical and Antiretroviral Susceptibility Characterization of Human Immunodeficiency Virus Subtypes B and Non-B in Pernambuco, Northeast Brazil.
    PLoS One. 2016;11:e0155854.
    PubMed     Text format     Abstract available


  217. FARSHADPOUR F, Taherkhani R, Tajbakhsh S, Gholizadeh Tangestani M, et al
    Prevalence and Trends of Transfusion-Transmissible Viral Infections among Blood Donors in South of Iran: An Eleven-Year Retrospective Study.
    PLoS One. 2016;11:e0157615.
    PubMed     Text format     Abstract available


  218. KIM YI, Kim HS, Park JW
    Higher Ratio of Serum Alpha-Fetoprotein Could Predict Outcomes in Patients with Hepatitis B Virus-Associated Hepatocellular Carcinoma and Normal Alanine Aminotransferase.
    PLoS One. 2016;11:e0157299.
    PubMed     Text format     Abstract available


  219. YEH CC, Wang WC, Wu CS, Sung FC, et al
    Association of Sjogrens Syndrome in Patients with Chronic Hepatitis Virus Infection: A Population-Based Analysis.
    PLoS One. 2016;11:e0161958.
    PubMed     Text format     Abstract available


  220. REMIS RS, Liu J, Loutfy MR, Tharao W, et al
    Prevalence of Sexually Transmitted Viral and Bacterial Infections in HIV-Positive and HIV-Negative Men Who Have Sex with Men in Toronto.
    PLoS One. 2016;11:e0158090.
    PubMed     Text format     Abstract available


  221. PIEPENBRINK MS, Samuel M, Zheng B, Carter B, et al
    Humoral Dysregulation Associated with Increased Systemic Inflammation among Injection Heroin Users.
    PLoS One. 2016;11:e0158641.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: